Host T Cells Affect Donor T Cell Engraftment and Graft-versus-Host Disease after Reduced-Intensity Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 9, 2007, Pages 1022-1030

  Hardy, Nancy M ^a   Hakim, Frances ^a   Steinberg, Seth M ^a   Krumlauf, Michael ^a   Cvitkovic, Romana ^a,b   Babb, Rebecca ^a   Odom, Jeanne ^a   Fowler, Daniel H ^a   Gress, Ronald E ^a   Bishop, Michael R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Graft versus host disease; Reduced intensity stem cell transplantation; T cells

Indexed keywords

CD3 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR IMMUNITY; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LIVING DONOR; LYMPHOCYTE COUNT; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PREDICTION; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD3; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547684352     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.05.008     Document Type: Article

References (29)

1. Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 94 (1999) 3234-3241
2. Baron F., Baker J.E., Storb R., et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 104 (2004) 2254-2262
3. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
4. Horwitz M.E., Barrett A.J., Brown M.R., et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 344 (2001) 881-888
5. Savage W.J., Bleesing J.J., Douek D., et al. Lymphocyte reconstitution following nonmyeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant 28 (2001) 463-471
6. Childs R., Chernoff A., Contentin N., et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343 (2000) 750-758
7. Rini B.I., Zimmerman T., Stadler W.M., Gajewski T.F., and Vogelzang N.J. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20 (2002) 2017-2024
8. Valcarcel D., Martino R., Caballero D., et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 31 (2003) 387-392
9. Keil F., Prinz E., Moser K., et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation 76 (2003) 230-236
10. Bishop M.R., Fowler D.H., Marchigiani D., et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 22 (2004) 3886-3892
11. Martin P.J. Influence of alloreactive T cells on initial hematopoietic reconstitution after marrow transplantation. Exp Hematol 23 (1995) 174-179
12. Sykes M., Shimizu I., and Kawahara T. Mixed hematopoietic chimerism for the simultaneous induction of T and B cell tolerance. Transplantation 79 (2005) S28-S29
13. Powell J.D., Fitzhugh C., Kang E.M., Hsieh M., Schwartz R.H., and Tisdale J.F. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation 80 (2005) 1541-1545
14. Barrell A.J., Mavroudis D., Tisdale J., et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21 (1998) 543-551
15. Johnson B.D., Becker E.E., and Truitt R.L. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 5 (1999) 123-132
16. Elmaagacli A.H., Peceny R., Steckel N., et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 101 (2003) 446-453
17. Bishop M.R., Steinberg S.M., Gress R.E., et al. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. Br J Haematol 126 (2004) 837-843
18. Fowler D.H., Odom J., Steinberg S.M., et al. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12 (2006) 1150-1160
19. Bishop M.R., Hou J.W., Wilson W.H., et al. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas. Biol Blood Marrow Transplant 9 (2003) 162-169
20. Luhm R.A., Bellissimo D.B., Uzgiris A.J., Drobyski W.R., and Hessner M.J. Quantitative evaluation of post-bone marrow transplant engraftment status using fluorescent-labeled variable number of tandem repeats. Mol Diagn 5 (2000) 129-138
21. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
22. Roux E., Helg C., Dumont-Girard F., Chapuis B., Jeannet M., and Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 87 (1996) 3984-3992
23. Ho V.T., and Soiffer R.J. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98 (2001) 3192-3204
24. Carvallo C., Geller N., Kurlander R., et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. Blood 103 (2004) 1560-1563
25. Dey B.R., McAfee S., Colby C., et al. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 9 (2003) 320-329
26. Hakim F.T., and Gress R.E. Reconstitution of the lymphocyte compartment after lymphocyte depletion: a key issue in clinical immunology. Eur J Immunol 35 (2005) 3099-3102
27. Golshayan D., Buhler L., Lechler R.I., and Pascual M. From current immunosuppressive strategies to clinical tolerance of allografts. Transpl Int 20 (2007) 12-24
28. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
29. Chakraverty R., Eom H.S., Sachs J., et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 108 (2006) 2106-2113